法瑞西单抗
Anti-Human VEGFAxANGPT2 (Faricimab; RG7716)
Catalog No:
CAS No.:
MDLNo:
Formula:
MW:
Size
Quantity
- +
Product Overview
Product Name Anti-Human VEGFAxANGPT2 (Faricimab; RG7716)
CAS1607793-29-2
Storage conditionstore at -20°C
Security information
Product details

Faricimab is a pioneering humanized bispecific antibody that targets both VEGF-A and Ang-2, offering a dual inhibition approach for retinal diseases like DME and nAMD. By inhibiting VEGF-A, it reduces endothelial cell proliferation and vascular permeability, while blocking Ang-2 is believed to enhance vascular stability and counteract VEGF-A effects. Faricimab has demonstrated a significant reduction in annual injections compared to other anti-VEGF treatments, with a comparable efficacy and safety profile, positioning it as a valuable treatment option for patients with retinal diseases.


Related
Sorry, no related items
History
Exbivirumab
Anti-Human VEGFAxANGPT2 (Faricimab; RG7716)
Anti-Human CD30 Monoclonal Antibody(Iratumumab)
Futuximab
Abituzumab (Anti-Integrin aV / ITGAV / CD51)
Trevogrumab (Synonyms: REGN-1033)
Anti-Human CD3xCD20 Bispecific Antibody (Mosunetuzumab; BTCT-4465A; R07030816;CD20-TDB; RG7828; CD20 CD3 bispecific antibody.)
Ramucirumab; LY3009806; IMC-1121B
Namilumab (Anti-CSF2 / GM-CSF)
Vatelizumab (Anti-Integrin a2b1 (ITGA2 & ITGB1))